Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of combining two medications, bimagrumab and semaglutide, in adults who are overweight or obese over a 48-week period.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 507 people

Who can join Ages 18–80 · all sexes

Timeline Started 2022-11 · est. completion 2025-06

Where 26 sites · Australia, New Zealand, United States

What this study is testing ClinicalTrials.gov NCT05616013 ↗

Description as written by the study sponsor.

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women

Treatments tested

Bimagrumab Biologic

Human monoclonal antibody to the activin receptor type II
Semaglutide also known as Wegovy, Ozempic Drug

Glucagon-like peptide-1 (GLP-1) receptor agonist
Placebo Other

Placebo

Main thing measured	Change From Baseline in Body Weight at Week 48
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Obese, Overweight or Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05616013 ↗